Ro entered into a GLP-1 research collaboration with Amgen; The best flu drug Americans aren’t taking; Richard Pazdur urges ...

In a report released yesterday, Geoff Meacham from Citi maintained a Hold rating on Amgen, with a price target of $315.00. The company’s shares closed yesterday at $325.54.

Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, ...

Amgen CEO Bob Bradway told CNBC's Jim Cramer he thinks his company's obesity drug can help patients maintain weight loss, ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

After a busy first day featuring headlines from a who's who of leading biopharma companies, the J.P. | The J.P. Morgan ...

Goldman Sachs reiterates Buy rating and $403 price target for Amgen due to strong portfolio execution and 6 key growth ...

Ro said on Tuesday it has entered a research collaboration with drugmaker ​Amgen to examine challenges patients and providers ...

Dragged down by negative returns for shares of Visa and Amgen, the Dow Jones Industrial Average is falling Tuesday morning.

The pharmaceutical industry is witnessing significant developments, including Merck's forecasted revenue surge to $70 billion ...

Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...

Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...